The following menu user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.
Destroy user interface control
Sign in to NCBI
[h=1]
PubMed[/h]
US National Library of Medicine National Institutes of Health
Search termSearch databaseThe following autocomplete user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.
Destroy user interface control
[h=2]Result Filters[/h]
The following popper user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.
Destroy user interface control[h=4]
Display Settings:[/h]
The following popper user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.
Destroy user interface control[h=4]
Send to:[/h]
Neuroscience. 2002;109(4):819-26.
[h=1]Two alpha(2)-adrenergic receptor subtypes, alpha(2A) and alpha(2C), inhibit transmitter release in the brain of gene-targeted mice.[/h]
Bücheler MM,
Hadamek K,
Hein L.
[h=3]Source[/h]Institut für Pharmakologie und Toxikologie, Universität Würzburg, Versbacher Strasse 9, 97078 Würzburg, Germany.
[h=3]Abstract[/h]alpha(2)-Adrenergic receptors play an essential role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the CNS. However, the role of each of the three highly homologous alpha(2)-adrenergic receptor subtypes (alpha(2A), alpha(2B), alpha(2C)) in this process has not been determined unequivocally. To address this question, the regulation of norepinephrine and dopamine release was studied in mice carrying deletions in the genes encoding the three alpha(2)-adrenergic receptor subtypes. Autoradiography and radioligand binding studies showed that alpha(2)-receptor density in alpha(2A)-deficient brains was decreased to 9 +/- 1% of the respective wild-type value, whereas alpha(2)-receptor levels were reduced to 83 +/- 4% in alpha(2C)-deficient mice. These results indicate that approximately 90% of mouse brain alpha(2)-receptors belong to the alpha(2A) subtype and 10% are alpha(2C)-receptors. In isolated brain cortex slices from wild-type mice a non-subtype-selective alpha(2)-receptor agonist inhibited release of [(3)H]norepinephrine by maximally 96%. Similarly, release of [(3)H]dopamine from isolated basal ganglion slices was inhibited by 76% by an alpha(2)-receptor agonist. In alpha(2A)-receptor-deficient mice, the inhibitory effect of the alpha(2)-receptor agonist on norepinephrine and dopamine release was significantly reduced but not abolished. Only in tissues from mice lacking both alpha(2A)- and alpha(2C)-receptors was no alpha(2)-receptor agonist effect on transmitter release observed. The time course of onset of presynaptic inhibition of norepinephrine release was much faster for the alpha(2A)-receptor than for the alpha(2C)-subtype. After prolonged stimulation with norepinephrine, presynaptic alpha(2C)-adrenergic receptors were desensitized. From these data we suggest that two functionally distinct alpha(2)-adrenergic receptor subtypes, alpha(2A) and alpha(2C), operate as presynaptic inhibitory receptors regulating neurotransmitter release in the mouse CNS.
PMID:11927164 [PubMed - indexed for MEDLINE]
Alpha-2A and Alpha-2C blockade results in an increase in epinephrine/Norepinephrine, Basal Ganglia Dopamine, and serotonin levels. The primary perceived effect, for me, is an increase in motivation and goal-fulfillment actions.
The difference in affinities also can explain Alpha-Yohimbine's distinct lack of anxiety effects as compared to Yohimbine.